GO:0050819 negative regulation of coagulation: Anticoagulant Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050819 (negative regulation of coagulation) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of coagulation.
• Coagulation is a tightly controlled protease cascade, and its negative regulation prevents excessive thrombin generation and pathological thrombosis.
• Key negative regulators include tissue factor pathway inhibitor (TFPI), antithrombin (SERPINC1), protein C (PROC), protein S (PROS1), and myeloperoxidase (MPO).
• Myeloperoxidase (MPO) acts as a negative regulator of phospholipid-dependent coagulation, linking inflammation to anticoagulant control.
• Dysregulated negative regulation of coagulation contributes to thrombosis, disseminated intravascular coagulation (DIC), and cancer-associated coagulopathy.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of anticoagulant genes in coagulation control.
Description
Coagulation is the physiological process by which blood forms clots to prevent hemorrhage, but uncontrolled activation can lead to thrombosis, organ damage, and death. The Gene Ontology term GO:0050819, negative regulation of coagulation, captures all biological processes that stop, prevent, or reduce the frequency, rate, or extent of coagulation. This term is essential for researchers because it defines the molecular brakes that keep the clotting cascade in check, and its disruption is a common feature of thrombotic and inflammatory diseases. Understanding negative regulation of coagulation requires integrating knowledge of protease inhibitors, endothelial anticoagulant pathways, and inflammation-driven modulators. Recent studies have shown that negative regulators such as myeloperoxidase (MPO) and long non-coding RNAs like MALAT1 can directly influence coagulation activation in disease contexts. This article provides a research-grade overview of GO:0050819, covering its definition, mechanisms, key genes, disease links, and CRISPR-based methods for experimental interrogation.
negative regulation of coagulation At A Glance
| GO ID | GO:0050819 |
|---|---|
| GO term | negative regulation of coagulation |
| Ontology | biological_process |
| Synonym | anticoagulant activity, down regulation of coagulation, down-regulation of coagulation, downregulation of coagulation, inhibition of coagulation, negative regulation of clotting |
| Definition | Any process that stops, prevents, or reduces the frequency, rate or extent of coagulation. |
| Major function | Restraining the coagulation protease cascade to prevent excessive thrombin generation and thrombosis. |
| Key regulators | TFPI, SERPINC1 (antithrombin), PROC (protein C), PROS1 (protein S), MPO. |
| Disease relevance | Thrombosis, disseminated intravascular coagulation, cancer-associated coagulopathy, inflammatory coagulopathy. |
| Research methods | CRISPR knockout/knock-in, coagulation assays, thrombin generation, mouse models. |
What Is GO:0050819?
GO:0050819 (negative regulation of coagulation) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of coagulation. Coagulation itself is the cascade of protease activation events that convert fibrinogen to fibrin, forming a blood clot. Negative regulation therefore encompasses anticoagulant mechanisms such as protease inhibition, cofactor inactivation, and downregulation of procoagulant signaling. This term is a biological_process in the Gene Ontology and includes synonyms such as anticoagulant activity, inhibition of coagulation, and negative regulation of clotting.
Why Is negative regulation of coagulation Important in Cell Biology?
Negative regulation of coagulation is critical because the coagulation cascade is a powerful amplification system that, if unchecked, can cause thrombosis, organ ischemia, and death. Anticoagulant pathways such as the protein C system and tissue factor pathway inhibitor (TFPI) provide essential brakes on clot formation. Inflammatory and infectious contexts, including gram-negative bacterial infection and acute myeloid leukemia (AML), can perturb these brakes and drive coagulopathy. Therefore, understanding GO:0050819 is fundamental for developing therapies that prevent thrombosis without causing bleeding.
• Prevents excessive thrombin generation and pathological thrombosis.
• Maintains hemostatic balance by counteracting procoagulant amplification.
• Limits clot propagation to the site of injury.
• Modulates inflammation-driven coagulation in sepsis and infection.
• Influences cancer-associated coagulopathy, including in AML.
• Provides therapeutic targets for anticoagulant drug development.
• Links vitamin K-dependent factors to broader health outcomes beyond coagulation.
• Involves gut microbiota and metabolic modulation in inflammatory disease models.
• Can be studied with CRISPR models to establish causality of candidate genes.
• Dysregulation contributes to disseminated intravascular coagulation (DIC).
What Happens During negative regulation of coagulation?
Initiation of anticoagulant pathways
In simple terms: The body starts its own clot-prevention system as soon as clotting begins.
Negative regulation of coagulation is initiated when procoagulant activity triggers counter-regulatory pathways, including tissue factor pathway inhibitor (TFPI) and the protein C anticoagulant system. TFPI binds and inhibits factor Xa and the tissue factor-factor VIIa complex, thereby dampening the initiation of coagulation. Protein C, activated by thrombin-thrombomodulin on endothelial cells, degrades factors Va and VIIIa, reducing thrombin generation. These pathways are essential for preventing runaway coagulation after vascular injury.
Amplification of anticoagulant signals
In simple terms: The anticoagulant response gets stronger to match the clotting signal.
Once initiated, anticoagulant signals are amplified through cofactor-dependent mechanisms. Protein S acts as a cofactor for activated protein C (APC) in the inactivation of factor Va and factor VIIIa. Antithrombin (SERPINC1) inhibits thrombin and factor Xa, and its activity is enhanced by heparin-like glycosaminoglycans on endothelial surfaces. Myeloperoxidase (MPO) has been identified as a negative regulator of phospholipid-dependent coagulation, further expanding the repertoire of anticoagulant modulators. These amplification steps ensure that coagulation remains localized and self-limited.
Inhibition of procoagulant proteases
In simple terms: Specific proteins block the enzymes that make clots.
The central mechanism of negative regulation of coagulation is direct inhibition of procoagulant proteases. Antithrombin forms irreversible complexes with thrombin, factor Xa, and other serine proteases, neutralizing their activity. TFPI inhibits factor Xa and the tissue factor-factor VIIa complex in a two-step mechanism. APC cleaves and inactivates factor Va and factor VIIIa, reducing the assembly of the prothrombinase and tenase complexes. These inhibitory events collectively reduce thrombin generation and fibrin formation.
Resolution and clearance of clotting components
In simple terms: The clot is broken down and the clotting machinery is cleared away.
After coagulation is controlled, negative regulation also involves clearance of activated clotting factors and resolution of the clot. Antithrombin-protease complexes are cleared from circulation, and fibrin is degraded by the fibrinolytic system. Inflammatory cells such as neutrophils can release MPO, which modulates phospholipid-dependent coagulation and may influence clot resolution. In infection, virus-induced coagulation activation is counterbalanced by negative regulatory pathways to prevent disseminated intravascular coagulation. The interplay between coagulation and inflammation is a key determinant of outcome in sepsis and cancer.
Integration with inflammation and immunity
In simple terms: The immune system and clotting system talk to each other to keep balance.
Negative regulation of coagulation is closely integrated with inflammatory and immune responses. The long non-coding RNA MALAT1 regulates gram-negative bacteria-induced coagulation via caspase-11 signaling, highlighting a role for non-coding RNAs in anticoagulant control. Myeloperoxidase (MPO) is a negative regulator of phospholipid-dependent coagulation and is released during inflammation. In AML, myeloperoxidase influences coagulation activation, linking heme enzyme activity to coagulopathy. These examples show that negative regulation of coagulation is not isolated but is modulated by immune and inflammatory signals.
Key Genes Involved in GO:0050819 negative regulation of coagulation
The following genes and proteins are central to negative regulation of coagulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SERPINC1 | Antithrombin; inhibits thrombin and factor Xa | Key anticoagulant; deficiency causes thrombosis |
| PROC | Protein C; inactivates factors Va and VIIIa | Major anticoagulant pathway; sepsis and thrombosis models |
| PROS1 | Protein S; cofactor for activated protein C | Deficiency linked to thrombophilia |
| TFPI | Tissue factor pathway inhibitor; inhibits TF-VIIa and Xa | Regulates initiation of coagulation |
| MPO | Myeloperoxidase; negative regulator of phospholipid-dependent coagulation | Links inflammation to anticoagulation; AML coagulopathy |
| MALAT1 | Long non-coding RNA; regulates gram-negative bacteria-induced coagulation via caspase-11 | Innate immunity and coagulation crosstalk |
| CASP11 | Caspase-11; mediates inflammatory coagulation signaling | Non-canonical inflammasome and coagulation |
| F2 | Prothrombin; substrate of anticoagulant proteases | Thrombin generation assays |
| F5 | Factor V; target of activated protein C | APC resistance and thrombosis |
| F8 | Factor VIII; target of activated protein C | Hemophilia and thrombosis models |
| F10 | Factor Xa; inhibited by TFPI and antithrombin | Coagulation cascade studies |
| F3 | Tissue factor; initiator of coagulation | Inflammation and thrombosis |
| VKORC1 | Vitamin K epoxide reductase; supports vitamin K-dependent factors | Warfarin response and coagulation |
| GGCX | Gamma-glutamyl carboxylase; modifies vitamin K-dependent proteins | Vitamin K biology |
| THBD | Thrombomodulin; cofactor for protein C activation | Endothelial anticoagulant function |
| EPCR | Endothelial protein C receptor; enhances protein C activation | Sepsis and coagulation |
| SERPIND1 | Heparin cofactor II; inhibits thrombin | Anticoagulant mechanisms |
How Is negative regulation of coagulation Regulated?
Negative regulation of coagulation is itself regulated at multiple levels. Transcriptional and post-transcriptional control of anticoagulant genes such as SERPINC1, PROC, and PROS1 influences the capacity to restrain coagulation. Inflammatory cytokines and pathogen-associated molecular patterns can modulate the expression of tissue factor and anticoagulant pathways, shifting the balance toward thrombosis. The long non-coding RNA MALAT1 regulates gram-negative bacteria-induced coagulation via caspase-11 signaling, illustrating non-coding RNA control of anticoagulant responses. Myeloperoxidase (MPO) activity is regulated by inflammatory stimuli and can directly influence phospholipid-dependent coagulation. Additionally, vitamin K status affects the gamma-carboxylation of vitamin K-dependent proteins, thereby regulating both pro- and anticoagulant factors. Gut microbiota and metabolic pathways can also modulate systemic inflammation and coagulation in disease models.
negative regulation of coagulation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SERPINC1 | Antithrombin deficiency and thrombosis | Knockout mouse and thrombin generation assays |
| PROC | Protein C deficiency and thrombophilia | Point-mutation knock-in models |
| MPO | AML-associated coagulopathy and inflammation | MPO knockout and overexpression cell models |
| MALAT1 | Gram-negative bacteria-induced coagulation | MALAT1 knockout and rescue models |
| F5 | APC resistance and venous thrombosis | Factor V Leiden knock-in model |
Thrombosis and cardiovascular disease
Impaired negative regulation of coagulation is a central mechanism in venous and arterial thrombosis. Deficiencies in antithrombin (SERPINC1), protein C (PROC), or protein S (PROS1) lead to excessive thrombin generation and thrombotic risk. Dysfunctional TFPI or APC resistance further shifts the hemostatic balance toward clot formation. These pathways are key targets for anticoagulant therapy and are studied using coagulation assays and genetic models.
Cancer-associated coagulopathy
Malignancies, including acute myeloid leukemia (AML), are frequently associated with activation of coagulation and thrombotic complications. Myeloperoxidase (MPO), a heme enzyme released by leukemic cells, has been shown to regulate coagulation activation in newly diagnosed AML. MPO also acts as a negative regulator of phospholipid-dependent coagulation, suggesting a complex role in cancer-associated coagulopathy. Understanding these mechanisms may inform risk stratification and therapeutic strategies in AML.
Infection and disseminated intravascular coagulation
Severe infections, particularly gram-negative bacterial sepsis, can trigger disseminated intravascular coagulation (DIC) when negative regulation of coagulation fails. MALAT1 regulates gram-negative bacteria-induced coagulation via caspase-11 signaling, linking innate immunity to anticoagulant control. Virus infections also modulate the coagulation protease cascade, with multiple roles for coagulation proteases during infection. These findings highlight the importance of negative regulatory pathways in preventing infection-associated thrombosis.
Inflammatory and metabolic disease
Chronic inflammatory conditions, including ulcerative colitis, involve gut microbiota and metabolic alterations that can influence systemic coagulation. Vitamin K status, which affects gamma-carboxylation of coagulation factors, has implications beyond coagulation in health and disease. Myeloperoxidase-mediated modulation of phospholipid-dependent coagulation provides a mechanistic link between inflammation and anticoagulation. These connections suggest that negative regulation of coagulation is relevant to a broad range of inflammatory and metabolic disorders.
From negative regulation of coagulation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SERPINC1 increase thrombin generation? | SERPINC1 knockout cell line and mouse model |
| Does a specific PROC mutation impair anticoagulant function? | PROC point-mutation knock-in |
| Does MPO negatively regulate phospholipid-dependent coagulation? | MPO knockout and overexpression models |
| Does MALAT1 regulate bacteria-induced coagulation? | MALAT1 knockout and caspase-11 rescue |
| Does TFPI inhibition alter tissue factor-driven coagulation? | TFPI knockout or knockdown |
| Does vitamin K status affect anticoagulant protein function? | GGCX or VKORC1 knockout models |
How to Study the negative regulation of coagulation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Thrombin generation assay | Kinetics of thrombin formation | Assessing anticoagulant capacity |
| aPTT/PT | Clotting time via intrinsic/extrinsic pathways | Screening for coagulation defects |
| CRISPR knockout | Loss-of-function effects on coagulation | Testing candidate anticoagulant genes |
| RNA-seq | Transcriptomic changes in coagulation genes | Identifying regulators in disease models |
| Proteomics | Protein abundance and modifications | Quantifying anticoagulant proteins |
| Western blot | Protein expression and cleavage | Validating MPO or APC effects |
| Flow cytometry | Cell surface tissue factor and platelet activation | Infection and inflammation studies |
| Mouse thrombosis models | In vivo thrombus formation | Preclinical testing of anticoagulant targets |
Coagulation assays and thrombin generation
Functional assessment of negative regulation of coagulation relies on assays such as activated partial thromboplastin time (aPTT), prothrombin time (PT), and thrombin generation assays. These methods measure the impact of anticoagulant pathways on clot formation and can be applied to CRISPR-edited cell lines or plasma samples. Thrombin generation assays are particularly useful for quantifying the balance between pro- and anticoagulant forces.
CRISPR screening and gene editing
CRISPR knockout and knock-in models enable causal testing of candidate genes in negative regulation of coagulation. For example, MALAT1 knockout can reveal its role in bacteria-induced coagulation, while MPO knockout can demonstrate its function as a negative regulator of phospholipid-dependent coagulation. Pooled CRISPR screens can identify novel anticoagulant genes in relevant cell types.
Transcriptomics and non-coding RNA analysis
RNA sequencing and non-coding RNA profiling can identify regulators of anticoagulant gene expression. MALAT1 is a long non-coding RNA that regulates coagulation via caspase-11 signaling, highlighting the value of lncRNA analysis. Transcriptomic studies in AML and inflammatory models can reveal how MPO and other factors modulate coagulation pathways.
Proteomics and post-translational modification analysis
Proteomic approaches can quantify anticoagulant proteins and their post-translational modifications, such as gamma-carboxylation of vitamin K-dependent factors. Mass spectrometry-based methods can detect antithrombin-protease complexes and other markers of coagulation activation. These techniques complement functional assays and CRISPR models.
How CRISPR Can Be Used to Study GO:0050819 negative regulation of coagulation
Knockout
CRISPR knockout of genes such as SERPINC1, PROC, or MPO can establish their causal role in negative regulation of coagulation. For example, MPO knockout models have been used to demonstrate its function as a negative regulator of phospholipid-dependent coagulation. MALAT1 knockout can reveal its role in gram-negative bacteria-induced coagulation. These models are essential for validating candidate anticoagulant genes.
Point Mutation
Point-mutation knock-in models can mimic naturally occurring variants in anticoagulant genes, such as PROC or PROS1 mutations associated with thrombophilia. These models allow precise interrogation of how specific amino acid changes affect protein function and coagulation control. They are particularly useful for studying APC resistance and factor V Leiden.
Knock-in
Knock-in of tagged or reporter constructs enables tracking of anticoagulant proteins in live cells and tissues. For example, tagging endogenous MPO or TFPI can reveal their localization and dynamics during coagulation. Knock-in models can also be used to express human variants in mouse models for preclinical studies.
Overexpression
Overexpression of anticoagulant genes such as TFPI, PROC, or SERPINC1 can test whether increased negative regulation reduces thrombosis in disease models. Overexpression of MALAT1 or MPO can also reveal gain-of-function effects on coagulation. These models complement knockout studies to provide a comprehensive view of gene function.
How EDITGENE Supports negative regulation of coagulation Research
Researchers studying negative regulation of coagulation-related genes often need to determine whether a candidate gene is causally involved in restraining the clotting cascade. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of coagulation research.
Frequently Asked Questions About negative regulation of coagulation
What is negative regulation of coagulation (GO:0050819)?
It is any biological process that stops, prevents, or reduces the frequency, rate, or extent of coagulation.
What genes are involved in negative regulation of coagulation?
Key genes include SERPINC1, PROC, PROS1, TFPI, MPO, and MALAT1.
How does antithrombin regulate coagulation?
Antithrombin inhibits thrombin and factor Xa, reducing thrombin generation and fibrin formation.
What is the role of protein C in anticoagulation?
Activated protein C inactivates factors Va and VIIIa, dampening the coagulation cascade.
How does myeloperoxidase (MPO) affect coagulation?
MPO acts as a negative regulator of phospholipid-dependent coagulation and is linked to AML coagulopathy.
What diseases are associated with impaired negative regulation of coagulation?
Thrombosis, disseminated intravascular coagulation, cancer-associated coagulopathy, and inflammatory diseases.
How can CRISPR be used to study negative regulation of coagulation?
CRISPR knockout, point mutation, knock-in, and overexpression models can test causal roles of anticoagulant genes.
What assays measure negative regulation of coagulation?
Thrombin generation assays, aPTT, PT, and proteomic analyses of anticoagulant proteins.
Is MALAT1 involved in coagulation regulation?
Yes, MALAT1 regulates gram-negative bacteria-induced coagulation via caspase-11 signaling.
What is the role of vitamin K in coagulation control?
Vitamin K is required for gamma-carboxylation of vitamin K-dependent coagulation factors, influencing both pro- and anticoagulant pathways.
Conclusion
GO:0050819 (negative regulation of coagulation) defines the essential biological processes that restrain the clotting cascade and prevent pathological thrombosis. Key regulators such as antithrombin, protein C, TFPI, MPO, and MALAT1 provide multiple layers of control that are critical in health and disease. Dysregulation of these pathways contributes to thrombosis, DIC, and cancer-associated coagulopathy, making them important therapeutic targets. CRISPR-based models from EDITGENE enable researchers to dissect the causal roles of these genes and accelerate discovery in anticoagulant biology.
References
- 1. Yuan C et al.. 2026. A critical role for MALAT1 in gram-negative bacteria-induced coagulation via regulation of caspase-11 signaling.. J Thromb Haemost 24(3):1014-1031 PMID: 41391567
- 2. Langer F et al.. 2023. Regulation of coagulation activation in newly diagnosed AML by the heme enzyme myeloperoxidase.. Thromb Res 229:155-163 PMID: 37473552
- 3. Esmon CT. 2000. Regulation of blood coagulation.. Biochim Biophys Acta 1477(1-2):349-60 PMID: 10708869
- 4. Norris LA. 2003. Blood coagulation.. Best Pract Res Clin Obstet Gynaecol 17(3):369-83 PMID: 12787532
- 5. Halder M et al.. 2019. Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease.. Int J Mol Sci 20(4) PMID: 30791399
- 6. Antoniak S et al.. 2014. Multiple roles of the coagulation protease cascade during virus infection.. Blood 123(17):2605-13 PMID: 24632711
- 7. Beckmann L et al.. 2017. Myeloperoxidase Is a Negative Regulator of Phospholipid-Dependent Coagulation.. Thromb Haemost 117(12):2300-2311 PMID: 29212118
- 8. Luo Y et al.. 2024. Banxia Xiexin decoction modulates gut microbiota and gut microbiota metabolism to alleviate DSS-induced ulcerative colitis.. J Ethnopharmacol 326:117990 PMID: 38423412
